CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0374 (clinicaltrials.gov NCT No: NCT01202877)
Title:A Combination of PKC412 and 5-azacytidine for the Treatment of Patients with Refractory, Relapsed or Untreated Acute Leukemia and Myelodysplastic Syndrome (MDS)
Principal Investigator:Jorge Cortes
Treatment Agent:5-Azacytidine; PKC412
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of
PKC412 (also called Midostaurin) and 5-azacytidine can help to control
refractory or relapsed acute leukemia and MDS. The safety and best dose of the
combination of the drugs will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:5-Azacytidine
PKC412
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Celgene Corporation
Novartis Pharmaceuticals
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults